Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma ALLO-316 Illustrates Proof-of-Concept in RCC and...

Related Keywords

United States ,California ,South San Francisco ,American ,Christine Cassiano ,Zachary Roberts ,Twitter ,Research Development ,Nasdaq ,California Institute For Regenerative Medicine ,Allogene Therapeutics Inc ,Drug Administration ,Technology To Optimize Cart Cell Expansion ,Therapeutics Development ,Corporate Affairs Brand Strategy ,American Cancer Society ,Ongoing Phase ,Metastatic Renal Cell Carcinoma ,Cell Expansion ,California Institute ,Regenerative Medicine ,Executive Vice President ,Chief Medical Officer ,Chimeric Antigen Receptor ,Abla Creasey ,Vice President ,Fast Track Designation ,Allogene Therapeutics ,Forward Looking Statements ,Private Securities Litigation Reform Act ,Annual Report ,Investor Contact ,Chief Corporate Affairs ,Brand Strategy Officer ,Markets ,